News Conference News CX Symposium 2025 Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices L.A. McKeown April 23, 2025
News Conference News TCT 2023 Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door? L.A. McKeown October 24, 2023
News Conference News ISET 2023 BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions Caitlin E. Cox January 20, 2023
News Conference News TCT 2020 IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs L.A. McKeown October 18, 2020
News Conference News LINC 2020 DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets L.A. McKeown January 30, 2020
News Conference News ISET 2020 FDA’s First Take on New Paclitaxel Concerns in CLI Caitlin E. Cox January 24, 2020
News Conference News VIVA 2019 IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB L.A. McKeown November 05, 2019
News Conference News TCT 2019 ‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures L.A. McKeown September 28, 2019
News Conference News VIVA 2017 Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD L.A. McKeown September 18, 2017
News Conference News TCT 2016 ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions L.A. McKeown November 07, 2016
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016
News Conference News VEITH 2015 DCBs for Femoropoliteal Disease: What’s Now and What’s Next? Yael L. Maxwell November 19, 2015
News Conference News EuroPCR 2015 Studies Provide Encouraging Results for DCB in Long SFA Lesions Caitlin E. Cox May 22, 2015
News Conference News TCT 2012 DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS October 24, 2012